Safety, Tolerability and Immunogenicity of an MF59-adjuvanted, Cell Culture-derived, A/H5N1, Subunit Influenza Virus Vaccine: Results From a Dose-finding Clinical Trial in Healthy Pediatric Subjects-Reference-Cited by-同舟云学术

Safety, Tolerability and Immunogenicity of an MF59-adjuvanted, Cell Culture-derived, A/H5N1, Subunit Influenza Virus Vaccine: Results From a Dose-finding Clinical Trial in Healthy Pediatric Subjects

Published:2019-07 Issue:7 Volume:38 Page:757-764
ISSN:0891-3668
Container-title:Pediatric Infectious Disease Journal
language:en
Short-container-title:

Author:

Chanthavanich Pornthep,Anderson Edwin,Kerdpanich Phirangkul,Bulitta Michael,Kanesa-thasan Niranjan,Hohenboken Matthew

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Microbiology (medical),Pediatrics, Perinatology, and Child Health

Reference24 articles.

1. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence.;Vesikari;Pediatrics,2010

2. Prevention of influenza: recommendations for influenza immunization of children, 2008–2009.;Pediatrics,2008

3. H5N1 avian influenza in children.;Oner;Clin Infect Dis,2012

4. Population-wide benefits of routine vaccination of children against influenza.;Weycker;Vaccine,2005

5. Influenza: options to improve pandemic preparation.;Rappuoli;Science,2012

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pandemic preparedness through vaccine development for avian influenza viruses;Human Vaccines & Immunotherapeutics;2024-05-28

2. Efficacy of cell culture-derived influenza vaccines for children: A systematic review and meta-analysis;Journal of Pediatric Pulmonology;2023

3. Phase 3 Randomized, Multicenter, Placebo-Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects;Vaccines;2022-03-23

4. Analyses of Safety Profile and Homologous Antibody Responses to a Mammalian Cell-Based, MF59-Adjuvanted, A/H5N1, Pandemic Influenza Vaccine across Four Phase II/III Clinical Trials in Healthy Children, Adults, and Older Adults;Vaccines;2021-12-11

5. Antibody responses against heterologous A/H5N1 strains for an MF59-adjuvanted cell culture–derived A/H5N1 (aH5N1c) influenza vaccine in healthy pediatric subjects;Vaccine;2021-11